V. Chiarion Sileni

发表

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

A. Hauschild, P. Ascierto, J. Larkin, 2017, European journal of cancer.

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

J. Utikal, A. Hauschild, D. Schadendorf, 2014, The New England journal of medicine.

Time to diagnosis in esophageal cancer: a cohort study

M. Rugge, V. Chiarion Sileni, A. Ruol, 2018, Acta oncologica.

A Therapeutic and Diagnostic Multidisciplinary Pathway for Merkel Cell Carcinoma Patients

F. Bassetto, S. Mocellin, V. Chiarion Sileni, 2020, Frontiers in Oncology.

Effects of Neoadjuvant Therapy on Perioperative Morbidity in Elderly Patients Undergoing Esophagectomy for Esophageal Cancer

V. Chiarion Sileni, A. Ruol, G. Portale, 2007, Annals of Surgical Oncology.

Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma

V. Chiarion Sileni, A. Ruol, S. Merigliano, 2001, Cancer.

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

P. Ascierto, E. Simeone, P. Queirolo, 2014, Journal of Neuro-Oncology.

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

A. Hauschild, D. Schadendorf, K. Flaherty, 2019, The New England journal of medicine.

Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program

P. Ascierto, P. Queirolo, V. Chiarion Sileni, 2021, Journal of translational medicine.

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

D. Mallardo, P. Ascierto, R. Dummer, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA45 First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study)

P. Ascierto, R. Dummer, P. Queirolo, 2020 .

Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.

D. Schadendorf, R. Dummer, J. Wolchok, 2022, Journal of Clinical Oncology.

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.

A. Hauschild, D. Schadendorf, R. Dummer, 2020, The New England journal of medicine.

Hybrid MOPP/ABVD and radiotherapy in advanced Hodgkin's disease.

V. Chiarion Sileni, G. Pappagallo, L. Salvagno, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Late relapses in Hodgkin's disease: outcome of patients relapsing more than twelve months after primary chemotherapy.

V. Chiarion Sileni, M. Fiorentino, G. Pappagallo, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients

V. Chiarion Sileni, A. Parisi, A. Vecchiato, 2018, Cancers.

Systemic treatments for metastatic cutaneous melanoma.

S. Mocellin, V. Chiarion Sileni, C. Rossi, 2014, The Cochrane database of systematic reviews.

Cholecystectomy during esophagectomy is safe but unnecessary

M. Rugge, V. Chiarion Sileni, A. Ruol, 2020, Acta chirurgica Belgica.

Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial.

G. Ceresoli, V. Chiarion Sileni, A. Paccagnella, 2004, Lung cancer.

Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma

N. Bartolomeo, G. Madonna, P. Ascierto, 2022, Journal of translational medicine.

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.

Dirk Schadendorf, Reinhard Dummer, Naoya Yamazaki, 2018, The Lancet. Oncology.

Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East

P. Ascierto, V. Chiarion Sileni, P. Lorigan, 2021, International journal of cancer.

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme

P. Ascierto, A. Testori, P. Queirolo, 2014, Journal of experimental & clinical cancer research : CR.

Interferon alpha for the adjuvant treatment of cutaneous melanoma.

S. Mocellin, V. Chiarion Sileni, M. Lens, 2013, The Cochrane database of systematic reviews.

Report from the Melanoma Independent Board First Melanoma MIB Conference, 21–22 October 2013

P. Ascierto, A. Testori, V. Chiarion Sileni, 2014, Ecancermedicalscience.

Melanoma M (Zero): Diagnosis and Therapy

V. Chiarion Sileni, M. Montesco, R. Stramare, 2013, ISRN Dermatology.

Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma

V. Chiarion Sileni, M. Alaibac, I. Russo, 2018, Scientifica.

A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience

V. Chiarion Sileni, A. Frigo, M. Alaibac, 2017, European Journal of Dermatology.

1092PDAN UPDATE ON OVERALL SURVIVAL (OS) AND FOLLOW-ON THERAPIES IN BREAK-3, A PHASE III, RANDOMIZED TRIAL: DABRAFENIB (D) VS. DACARBAZINE (DTIC) IN PATIENTS (PTS) WITH BRAF V600E MUTATION-POSITIVE METASTATIC MELANOMA (MM).

A. Hauschild, C. Blank, V. Chiarion Sileni, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Leucovorin calcium enhancement of mucositis after continuous infusion fluorouracil and short infusion cisplatin.

V. Chiarion Sileni, V. Fosser, M. Gulisano, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial.

A. Hauschild, D. Schadendorf, R. Dummer, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial.

A. Hauschild, D. Schadendorf, R. Dummer, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup

V. Chiarion Sileni, M. Guida, G. Biasco, 2004, Melanoma research.

Treatment of multiple myeloma with M-2 protocol and without maintenance therapy.

V. Chiarion Sileni, A. Paccagnella, L. Salvagno, 1983, European journal of cancer & clinical oncology.

A multicenter phase II study of induction CT with FOLFOX-4 and cetuximab followed by RT and cetuximab in locally advanced esophageal cancer (LAEC).

V. Chiarion Sileni, A. Ruol, F. Ciardiello, 2009, Journal of Clinical Oncology.

Estimation of direct costs of melanoma in the Veneto Region: a budget assessment and cost-consequence analysis.

V. Chiarion Sileni, M. Montesco, A. Buja, 2018, Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia.

The Pattern of Progression to First-Line Treatment with Dabrafenib and Trametinib in Patients with Unresectable or Metastatic, BRAF-Mutated, Cutaneous Melanoma: Results of the Observational T-WIN Study

P. Queirolo, M. Del Vecchio, V. Chiarion Sileni, 2023, Cancers.

Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive melanoma with central nervous system (CNS) metastases (mets): Primary results from phase 2 Tricotel study.

P. Ascierto, R. Dummer, H. Tawbi, 2022, Journal of Clinical Oncology.

Gastric non-Hodgkin's lymphoma: analysis of 252 patients from a multicenter study.

V. Chiarion Sileni, C. Doglioni, D. Nitti, 1999, Tumori.

Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile.

P. Ascierto, E. Simeone, P. Queirolo, 2023, European Journal of Cancer.